AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
69.88
+0.03 (0.04%)
At close: Jun 30, 2025, 4:00 PM
69.55
-0.33 (-0.47%)
After-hours: Jun 30, 2025, 7:57 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$54.98B
Revenue Growth
+15.48%
P/S Ratio
3.91
Revenue / Employee
$583,054
Employees
94,300
Market Cap
215.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
AZN News
- 3 days ago - Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium - Accesswire
- 6 days ago - AstraZeneca's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. - WSJ
- 6 days ago - US approves AstraZeneca, Daiichi's treatment for lung cancer - Reuters
- 16 days ago - 5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List - Seeking Alpha
- 17 days ago - AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion - WSJ
- 17 days ago - AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC - Reuters
- 27 days ago - Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - CNBC
- 4 weeks ago - 'Transformational' new drug could stop breast cancer tumours before they grow, trial finds - Skynews